- Home
- GAMB vs MSLE Comparison
GAMB vs MSLE Comparison
Compare GAMB & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAMB | MSLE |
|---|---|---|
| Founded | 2006 | N/A |
| Country | Jersey | Canada |
| Employees | N/A | 17 |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 146.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GAMB | MSLE |
|---|---|---|
| Price | $3.67 | $7.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.36 | N/A |
| AVG Volume (30 Days) | ★ 599.4K | 103.3K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.06 | N/A |
| Revenue Next Year | $8.79 | N/A |
| P/E Ratio | $89.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.58 | $5.50 |
| 52 Week High | $13.83 | $13.39 |
Technical Indicators
Market Signals| Indicator | GAMB | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 47.74 |
| Support Level | N/A | $6.67 |
| Resistance Level | $4.55 | $7.52 |
| Average True Range (ATR) | 0.16 | 0.66 |
| MACD | 0.00 | 0.27 |
| Stochastic Oscillator | 23.40 | 83.65 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.